• Publications
  • Influence
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
High-dose targeted radiotherapy with 7.4 GBq/m(2) of the radiolabeled somatostatin analog (90)Y-DOTATOC is a well-tolerated treatment for neuroendocrine tumors, with remarkable clinical benefit and objective response.
Synthesis and Evaluation of Bombesin Derivatives on the Basis of Pan-Bombesin Peptides Labeled with Indium-111, Lutetium-177, and Yttrium-90 for Targeting Bombesin Receptor-Expressing Tumors
These radiopeptides were composed of the first pan-bombesin radioligands, which show great promise for the early diagnosis of tumors bearing not only gastrin-releasing peptide-receptor–positive organs but also the other two bombesin receptor subtypes and may be of use in targeted radiotherapy of these tumors.
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Treatment with radiolabeled somatostatin analogs is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumors, and results obtained with [(90)Y-DOTA(0),Tyr(3)]octreotide and [(177)Lu-Dota(0,Tyr (3)] octreotate are very encouraging in terms of tumor regression.
Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
Treatment of neuroendocrine tumors with radiolabeled sst antagonists is clinically feasible and may have a significant impact on peptide receptor radionuclide therapy.
68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals.
PET (positron emission tomography) is a powerful diagnostic and imaging technique which requires short-lived positron emitting isotopes. The most commonly used are accelerator-produced (11)C and
Glucagon-like peptide-1 receptor imaging for localization of insulinomas.
In vivo GLP-1R imaging is an innovative, noninvasive diagnostic approach that successfully localizes small insulinomas pre- and intraoperatively and that may in the future affect the strategy of insulinoma localization.
Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of Cancer
Recent developments in the field of small peptides, and their applications in the diagnosis and treatment of cancer are presented.
Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid–Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission
G protein–coupled receptor agonists are being used as radiolabeled vectors for in vivo localization and therapy of tumors and GRP-based radioantagonists seem to be superior to radioagonists for in vitro imaging and potentially also for targeted radiotherapy of GRPR-positive tumors.
Radiopeptide Imaging and Therapy in Europe
Receptor targeting with radiolabeled peptides has become an important topic, particularly in nuclear oncology, and new radiopeptides targeting other G-protein–coupled receptors are entering the clinic, among them glucagon-like peptide 1 receptor–targeting molecules.
Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters.
The hypothesis that an additional NLS sequence to the DOTA-TOC could not only provide a better carrier for Auger electron-emitting radionuclides but also ensure a longer radioactivity retention time in the tumor cell is supported.